CGE

Clopidogrel

Find entries where: CGE

is present as a standalone ligand in 2 entries

Find related ligands:

Chemical Component Summary
Name	Clopidogrel
Synonyms	methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoate
Identifiers	methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)ethanoate
Formula	C₁₆ H₁₆ Cl N O₂ S
Molecular Weight	321.822
Type	NON-POLYMER
Isomeric SMILES	COC(=O)[C@H](c1ccccc1Cl)N2CCc3c(ccs3)C2
InChI	InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1
InChIKey	GKTWGGQPFAXNFI-HNNXBMFYSA-N

Chemical Details
Formal Charge	0
Atom Count	37
Chiral Atom Count	1
Bond Count	39
Aromatic Bond Count	11

Drug Info: DrugBank

DrugBank ID	DB00758
Name	Clopidogrel
Groups	approved
Description	Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213] It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.[A180547] Clopidogrel was granted FDA approval on 17 November 1997.[L7213]
Synonyms	Clopidogrel Clopidogrel bisulfate Clopidogrelum Clopidogrel besilate (+)-Clopidogrel Clopidogrel hydrochloride
Brand Names	Sandoz Clopidogrel Clopidogrel/acetylsalicylic Acid Mylan Clopidogrel bisulfate Duoplavin Rbx-clopidogrel Clopidogrel Krka Abbott-clopidogrel Clopidogrel Viatris Clopidogrel Sandoz Clopidogrel Bms Ag-clopidogrel Nra-clopidogrel Clopidogrel Teva Clopidogrel Ratiopharm Gmbh Clopidogre Ratiopharm Dom-clopidogrel Clopidogrel Teva Pharma B.V. Clopidogrel Acino Taro-clopidogrel Zyllt Mylan-clopidogrel Mint-clopidogrel Priva-clopidogrel Act Clopidogrel Clopidogrel 1a Pharma Clopidogrel Acino Pharma Gmbh Jamp-clopidogrel Clopidogrel Mylan M-clopidogrel Plavix Clopidogrel Acino Pharma Clopidogrel/acetylsalicylic Acid Zentiva Clopidogrel Hcs Q-clopidogrel Clopidogrel Krka D.D. Grepid Clopidogrel Hexal Clopidogrel Bisulfate Clopidogrel Tad Clopidogrel Zentiva Accel-clopidogrel Clopidogrel Kit Clopidogrel Bgr Bio-clopidogrel Mar-clopidogrel Apo-clopidogrel Clopido Grel 1a Pharma Auro-clopidogrel PMS-clopidogrel Clopidogrel Iscover Riva-clopidogrel Ipg-clopidogrel Torrent-clopidogrel Teva-clopidogrel Plavi Clopidogrel Qualimed Clopidogrel Apotex Clopidogrel Ratiopharm
Indication	Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213]
Categories	Antiplatelet agents Blood and Blood Forming Organs Cytochrome P-450 CYP1A2 Substrates Cytochrome P-450 CYP2B6 Inhibitors Cytochrome P-450 CYP2B6 Inhibitors (moderate) Cytochrome P-450 CYP2B6 Substrates Cytochrome P-450 CYP2C19 Substrates Cytochrome P-450 CYP2C8 Inhibitors Cytochrome P-450 CYP2C8 Inhibitors (strong) Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) Cytochrome P-450 CYP2C9 Substrates Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 CYP3A5 Substrates Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Substrates Decreased Platelet Aggregation Hematologic Agents Heterocyclic Compounds, Fused-Ring Neurotransmitter Agents OCT1 inhibitors OCT2 Inhibitors P-glycoprotein substrates P2Y12 Platelet Inhibitor Platelet Aggregation Inhibitors Excl. Heparin Purinergic Agents Purinergic Antagonists Purinergic P2 Receptor Antagonists Purinergic P2Y Receptor Antagonists Pyridines Sulfur Compounds Thienopyridines Thiophenes
ATC-Code	B01AC04
CAS number	113665-84-2

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
P2Y purinoceptor 12	MQAVDNLTSAPGNTSLCTRDYKITQVLFPLLYTVLFFVGLITNGLAMRIF...	unknown	antagonist
Cytochrome P450 2C9	MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI...	unknown	substrate,inhibitor
Cytochrome P450 1A2	MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...	unknown	substrate
Cytochrome P450 2C8	MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDI...	unknown	inhibitor
Liver carboxylesterase 1	MWLRAFILATLSASAAWGHPSSPPVVDTVHGKVLGKFVSLEGFAQPVAIF...	unknown	substrate
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	substrate
Cytochrome P450 2B6	MELSVLLFLALLTGLLLLLVQRHPNTHDRLPPGPRPLPLLGNLLQMDRRG...	unknown	substrate,inhibitor
Cytochrome P450 3A5	MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNV...	unknown	substrate
Cytochrome P450 2C19	MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDV...	unknown	substrate
Serum albumin	MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIA...	unknown	binder
P-glycoprotein 1	MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY...	unknown	substrate
Solute carrier family 22 member 1	MPTVDDILEQVGESGWFQKQAFLILCLLSAAFAPICVGIVFLGFTPDHHC...	unknown	inhibitor
Solute carrier family 22 member 2	MPTTVDDVLEHGGEFHFFQKQMFFLLALLSATFAPIYVGIVFLGFTPDHR...	unknown	inhibitor
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682